The ASCENT Clinical Trials – Multiple Locations

Back to Study

Details

Location: Multiple Locations
Age: 55 to 85
Duration: Up to a year.
Visits: Up to approximately 23 visits.

Click Here to Learn More

Eligibility Requirements

You or a loved one may qualify if you or they:

Are 55 to 85 years old
Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
Have gradual and progressive change in memory function for at least 6 months
Are willing and able to complete brain imaging (MRI and PET Scans)

There are additional clinical trial requirements to participate. A clinical trial representative will discuss them with potential participants.

Enter Contact Info

Please provide your contact information and a member of the study team will contact you to follow up.

First Name*

Last Name *

Phone Number *

Email *

I have reviewed the eligibility requirements *

You or a loved one may qualify if you or they:

Are 55 to 85 years old
Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
Have gradual and progressive change in memory function for at least 6 months
Are willing and able to complete brain imaging (MRI and PET Scans)

There are additional clinical trial requirements to participate. A clinical trial representative will discuss them with potential participants.

I authorize the release of my contact information to the study team. *

I'm Not Ready

Thank you for your interest in this study. You're bringing us one step closer to our goal of ending Alzheimer's

Your contact information will be shared with the study team. If you have any questions, please contact the study team:

Medical University of South Carolina (MUSC)

Email: [email protected]

About the Study:

Participants will be placed by chance into a clinical trial treatment group to receive the investigational drug PRX012 or placebo.

A placebo has no active ingredient and is used to compare the effects of the investigational drug. The placebo will look like the investigational drug and will be administered the same way. Participants and the clinical trial doctor will not know which treatment group s/he are in. This is the best way to measure the effect of the investigational drug, PRX012.

Compensation will be provided for clinical trial participation. Clinical trial related travel reimbursements may be provided. No health insurance is needed.

Purpose:

The investigational drug, PRX012, is designed to target, and potentially clear amyloid plaques (abnormal clumps) found in the brains of people with Alzheimer’s disease. The direct link between amyloid reduction and improvement in memory loss has not been established but is being further explored.

What is Involved:

Eligible participants are randomized to receive either the placebo or investigational drug, PRX012, at predetermined dose strengths. Participants will be monitored for safety and tolerability throughout the clinical trial, including a follow-up visit after the final dose.

Participants will take part in the following periods of the clinical trial after signing a consent form:

Screening – Up to approximately 10 weeks
Study Treatment – Approximately 24 weeks. Where participants will receive the study drug.
Follow-Up – Additional 26 weeks for further procedures.